Prolonged response to oral gefitinib, cyclophosphamide, and topotecan in heavily pretreated relapsed stage 4 neuroblastoma: a case report

J Pediatr Hematol Oncol. 2007 Nov;29(11):799-803. doi: 10.1097/MPH.0b013e31815815f6.

Abstract

A girl with metastatic neuroblastoma diagnosed at 4 years of age experienced an early disseminated relapse after high-dose chemotherapy. After reinduction, compassionate treatment with gefitinib (250 mg/d fixed dose) with oral topotecan (0.8 mg/m(2)/d) and cyclophosphamide (50 mg/m(2)/d) for 14 consecutive days, each course repeated every 28 days, was administered. Complete marrow clearance and metaiodobenzylguanidine response were achieved after 4 courses. After the first course, topotecan and cyclophosphamide were reduced by 25% for grade 4 hematologic toxicity. Subsequent courses were well tolerated. The girl remained progression free for 27 months. This combination may represent a viable therapeutic option and deserves further evaluation in resistant neuroblastoma.

Publication types

  • Case Reports

MeSH terms

  • Administration, Oral
  • Adrenal Gland Neoplasms / diagnostic imaging
  • Adrenal Gland Neoplasms / drug therapy*
  • Antineoplastic Combined Chemotherapy Protocols*
  • Child, Preschool
  • Cyclophosphamide / administration & dosage*
  • Female
  • Gefitinib
  • Humans
  • Neuroblastoma / diagnostic imaging
  • Neuroblastoma / drug therapy*
  • Quinazolines / administration & dosage*
  • Radionuclide Imaging
  • Recurrence
  • Topotecan / administration & dosage*
  • Treatment Outcome

Substances

  • Quinazolines
  • Topotecan
  • Cyclophosphamide
  • Gefitinib